The company is seeking approval for tucatinib, combined with two other drugs, for patients with HER2-positive breast cancer who have had at least three prior HER2-targeting therapies.
Topline data from the Phase II study of tucatinib showed the drug combined with an antibody-chemotherapy combination improved progression-free survival over the doublet by itself. Seattle Genetics acquired the drug when it bought Cascadian for $614 million last year.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.